UAB was part of a groundbreaking trial that is believed to be the first time it has been proved that the risk of mild cognitive impairment and dementia can be reduced through high blood-pressure treatment.
Significant novel findings published by UAB researchers established verapamil as a successful therapeutic approach to target loss of beta cell function caused by Type 1 diabetes.
Biomedical scientists and engineers can participate in a nationwide program that helps take their discoveries from the research lab to the clinical setting.
A diabetes drug suggests potential therapy for idiopathic pulmonary fibrosis, based on research with human lung fibroblasts and a mouse model of lung fibrosis.
In a large-scale analysis, Jeremy Blackburn, Ph.D., and collaborators found that the misuse of web archive services cause loss of ad revenue for popular news websites.
By using an injected biomarker, researchers are able to have a more accurate reading of kidney function in a clinical setting in half the time it used to take.
UAB researchers have identified a subgroup of heart failure patients with reductive stress who may be less responsive or even harmed by antioxidants, which could lead to personalized treatment and better outcomes.
A neuron model of Parkinson’s disease and Lewy body dementias shows defects that could suggest treatments to halt or reverse cognitive impairments before the neurons die.
The UAB-led clinical trial intends to provide multiple myeloma patients a treatment plan that eradicates their disease and enables them to live a life without ongoing treatment.
UAB is an Equal Opportunity/Affirmative Action Employer committed to fostering a diverse, equitable and family-friendly environment in which all faculty and staff can excel and achieve work/life balance irrespective of race, national origin, age, genetic or family medical history, gender, faith, gender identity and expression as well as sexual orientation. UAB also encourages applications from individuals with disabilities and veterans.